Results 111 to 120 of about 188,535 (344)

Bacteria‐Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy

open access: yesAdvanced Materials, EarlyView.
Bacteria‐responsive nanocarriers are designed to release antimicrobials only in the presence of infection‐specific cues. This selective activation ensures drug release precisely at the site of infection, avoiding premature or indiscriminate release, and enhancing efficacy.
Guillermo Landa   +3 more
wiley   +1 more source

Non-Alcoholic Fatty Liver Disease

open access: yesProceedings of Singapore Healthcare, 2010
Non-alcoholic fatty liver disease (NAFLD) comprises a disease spectrum ranging from benign hepatic steatosis to non-alcoholic steatohepatitis with inflammation (NASH) and liver cirrhosis.
Hui-Hui Tan MRCP(UK), FAMS   +1 more
doaj   +1 more source

Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets [PDF]

open access: yes, 2013
Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in children. NAFLD has emerged to be extremely prevalent, and predicted by obesity and male gender.
Giorgio V   +3 more
core   +1 more source

End‐to‐End Sensing Systems for Breast Cancer: From Wearables for Early Detection to Lab‐Based Diagnosis Chips

open access: yesAdvanced Materials Technologies, EarlyView.
This review explores advances in wearable and lab‐on‐chip technologies for breast cancer detection. Covering tactile, thermal, ultrasound, microwave, electrical impedance tomography, electrochemical, microelectromechanical, and optical systems, it highlights innovations in flexible electronics, nanomaterials, and machine learning.
Neshika Wijewardhane   +4 more
wiley   +1 more source

Role of High-Mobility Group Box-1 in Liver Pathogenesis [PDF]

open access: yes, 2019
High-mobility group box 1 (HMGB1) is a highly abundant DNA-binding protein that can relocate to the cytosol or undergo extracellular release during cellular stress or death. HMGB1 has a functional versatility depending on its cellular location.
Huda, Nazmul   +3 more
core   +1 more source

Gut Microbiota‐Derived Anandamide Mediates the Therapeutic Effects of Urolithin A on Alcohol‐Induced Cognitive and Social Dysfunction via CB1R‐DRD2‐RAP1 Signaling Axis

open access: yesAdvanced Science, EarlyView.
This study reveals that Urolithin A (UA) counteracts alcohol‐induced cognitive and social dysfunction (AICSD) via a gut microbiome‐dependent mechanism. UA‐enriched Bacteroids sartorii and Parabacteroids distasonis elevate anandamide (AEA), which activates the CB1R‐DRD2‐Rap1 signaling cascade to drive synaptic repair and reduce neuroinflammation ...
Hongbo Zhang   +9 more
wiley   +1 more source

Relationship between adipose tissue dysfunction, Vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease [PDF]

open access: yes, 2017
Non-alcoholic fatty liver disease ( NAFLD) is the most common chronic liver disease worldwide. Its pathogenesis is complex and not yet fully understood.
BARCHETTA, ILARIA   +7 more
core   +1 more source

A Novel Function of Nonadecanoic Acid in Regulating Glucose Homeostasis

open access: yesAdvanced Science, EarlyView.
This study identifies the odd‐chain fatty acid C19:0 as an endogenous ligand of GPR120 that promotes glucose homeostasis via Gαq signaling. In obesity, elevated palmitic acid suppresses endogenous C19:0 production through a miRNA–PPARα–HACL1 pathway, offering a promising direction for understanding the role of OCFAs in human health.
Yanting Hou   +14 more
wiley   +1 more source

Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation [PDF]

open access: yes, 2015
BACKGROUND: Liver biopsy is the reference standard for diagnosing the extent of fibrosis in chronic liver disease; however, it is invasive, with the potential for serious complications.
  +503 more
core   +2 more sources

Testicular mRNA‐LNP Delivery: A Novel Therapy for Genetic Spermatogenic Disorders

open access: yesAdvanced Science, EarlyView.
In the current study, we developed a novel therapy for genetic spermatogenic disorders. It was revealed that in vivo delivery of mRNA LNP3 could restore spermatogenesis in Msh5D486Y/D486Y and Maps KO mouse models with meiotic arrest. Notably, the offspring without genomic integration was born using ICSI derived from the rescue of Msh5D486Y/D486Y mouse ...
Chenwang Zhang   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy